ORGANIGRAM GLOBAL INC.

Organigram Global Inc. provided a business update highlighting the initial operating performance of its acquired Sanity Group and continued strength in its Canadian market share. Sanity Group has maintained approximately 10% market share in Germany and performed in line with revenue expectations since its acquisition in April 2026. In Canada, Organigram continues to lead in flower and vape categories, with overall recreational cannabis market share improving sequentially in June. The company also announced it expects to report its Q3 Fiscal 2026 results, including Sanity's financials, around August 11, 2026, and will host a Digital Investor Session in late September 2026.

Organigram Global reported a net loss of $0.92 million for Q2 Fiscal 2026, a significant decrease from a net income of $42.46 million in Q2 Fiscal 2025, with net revenue declining 9% to $59.79 million. The company recognized a $5.8 million impairment charge due to new US regulatory restrictions affecting hemp-derived products. Subsequent to the quarter, Organigram closed the acquisition of Sanity Group for €107.3 million and updated its Fiscal 2026 guidance, projecting net revenue to exceed $350 million and Adjusted EBITDA to surpass Fiscal 2025 performance.

Organigram Global Inc. announced it will report its second quarter fiscal 2026 results, for the period ended March 31, 2026, on Tuesday, May 12, 2026, before market open. The company will host a conference call at 8:00 am Eastern Time on the same day to discuss the results. Details for registration and webcast access have been provided, with a replay available online for 90 days.